{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-264616","form_type":"8-K","ticker":"TEM","cik":"0001717115","company_name":"Tempus AI, Inc.","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.243046+00:00","generated_at":"2026-05-17T00:39:35.854519+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Tempus AI Q3 revenue $334M (+84.7% YoY); turns positive adjusted EBITDA; raises FY guidance","bullets":["Revenue $334.2M, +84.7% YoY; gross profit $209.9M, +98.4% YoY.","Adjusted EBITDA positive $1.5M vs ($21.8M) loss YoY; net loss ($80.0M) includes $35M stock comp and $12M debt extinguishment loss.","Genomics revenue $252.9M (+117.2% YoY); Data and services $81.3M (+26.1%).","2025 revenue guidance raised to ~$1.265B (~80% growth); Q4 Adj. EBITDA expected ~$20M.","Acquired Paige (AI digital pathology); 217k clinical tests delivered (+33% YoY)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-264616","json":"https://secwatch.observer/filing/0001193125-25-264616.json","markdown":"https://secwatch.observer/filing/0001193125-25-264616.md","text":"https://secwatch.observer/filing/0001193125-25-264616.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1717115/000119312525264616/0001193125-25-264616-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1717115/000119312525264616/tem-20251104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:39:35.854519+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}